期刊文献+

比卡鲁胺联合化疗治疗去势抵抗性前列腺癌的临床分析 被引量:8

Clinical results of combination of bicalutamide and chemotherapy for castration resistant prostate cancer
下载PDF
导出
摘要 目的探讨晚期去势抵抗性前列腺癌安全、有效的治疗方法。方法以比卡鲁胺作为二线抗雄激素药物,联合多西紫杉醇加泼尼松化疗治疗26例去势抵抗性前列腺癌患者,观察疗效及毒副反应。结果 26例去势抵抗性前列腺癌患者25例有效,有效率为96.15%。最常见的毒副反应是骨髓抑制,可耐受。结论比卡鲁胺作为二线抗雄激素药物联合多西紫杉醇加泼尼松化疗治疗去势抵抗性前列腺癌的临床疗效明显,毒副反应轻,可作为晚期去势抵抗性前列腺癌的治疗策略。 Objective To explore the safe,effective treatment for castration resistant prostate cancer.Methods 26 cases with castration resistant prostate cancer enrolled in this study.All patients adopted bicalutamide as secondary anti-androgens and combined with chemotherapy of docetaxel plus prednisone acetate,and their efficacy and side effects evaluated.Results After therapy,25 patients in 26 cases with castration resistant prostate cancer were effective.The main toxicities were well-tolerated arrest of bone marrow.Conclusions The treatment of bicalutamide as secondary anti-androgens combined with the chemotherapy of docetaxel plus prednisone acetate is effective and well-tolerated for castration resistant prostate cancer patients.
出处 《现代泌尿生殖肿瘤杂志》 2011年第6期338-340,共3页 Journal of Contemporary Urologic and Reproductive Oncology
关键词 前列腺肿瘤 比卡鲁胺 多西紫杉醇 Prostatic neoplasms Bicalutamide Docetaxel
  • 引文网络
  • 相关文献

参考文献7

  • 1Scher HI,Halabi S,Tannock IF,et al.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:Recommendations of the prostate cancer clinical trials working group[J].J Clin Oncol,2008,26(7):1148-1159. 被引量:1
  • 2Lam JS,Leppert JT,Vemulapalli SN,et al.Secondary hormonal therapy for advanced prostate cancer[J].J Urol,2006,175(1):27-34. 被引量:1
  • 3Smith DC,Dunn RL,Strawderman MS,et al.Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer[J].J Clin Oncol,1998,16(5):1835-1843. 被引量:1
  • 4Heidenreich A,Aus G,Bolla M,et al.EAU guidelines on prostate cancer[J].Eur Urol,2008,53(1):68-80. 被引量:1
  • 5Kucuk O,Fisher E,Moinpour CM,et al.Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed a South-west Oncology Group study (SWOG 9235)[J].Urology,2001,58(1):53-58. 被引量:1
  • 6华立新,吴宏飞,眭元庚,徐正铨,张炜,钱立新,居小兵,张杰秀.比卡鲁胺治疗激素抵抗性前列腺癌[J].中华泌尿外科杂志,2005,26(6):383-385. 被引量:9
  • 7Tannock IF,de Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351(15):1502. 被引量:1

二级参考文献11

  • 1Goktas S, Grawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol, 1999,26:162-173. 被引量:1
  • 2Scher HI, Steineck G, Kelly WK. Hormone-refractory ( D3 ) prostate cancer:refining the concept. Urology,1995,46:142-148. 被引量:1
  • 3Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase Ⅱ clinical trial in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 1999,17:3461-3467. 被引量:1
  • 4Lara JP, Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest, 1999,17:137-144. 被引量:1
  • 5Joyce R,Fenton MA,Rode P,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.J Urol, 1998,159:149-153. 被引量:1
  • 6Kucuk O, Fisher E, Moinpour CM, et al. Phase Ⅱ trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group Study ( SWOG 9235). Urology,2001,58 :53-58. 被引量:1
  • 7Kolvenbag JCM, Blackledge GRP. Worldwide activity and safety of bicalutamide: A summary review. Urology, 1996,47: 70 -79. 被引量:1
  • 8孙颖浩,高旭.激素非依赖性前列腺癌及其诊断[J].中华泌尿外科杂志,2000,21(5):316-318. 被引量:17
  • 9鲍镇美.晚期前列腺癌的治疗新动向[J].中华泌尿外科杂志,2002,23(2):69-71. 被引量:47
  • 10华立新,吴宏飞,眭元庚,徐正铨,程双管.抗雄激素撤除综合征[J].中华泌尿外科杂志,2002,23(2):86-87. 被引量:3

共引文献8

同被引文献79

引证文献8

二级引证文献32

;
使用帮助 返回顶部